AzTrials
AzTrials

Chronic PeriodontitisNCT02195765

Randomized Clinical Trial of Enamel Matrix Derivative: Radiographic Analysis

A study testing enamel matrix derivative and Open flap debridement in people with Chronic Periodontitis, run by University of Sao Paulo at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a split-mouth, double-blind randomized controlled trial. Computerized linear radiographic measurements were used to detect infrabony defects treated with open flap debridement (OFD) or OFD associated with enamel matrix derivative (EMD), after 24 months. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Chronic Periodontitis
What is being tested?
enamel matrix derivative and Open flap debridement
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
1 siteBrazil
Study dates
Jun 2002to Oct 2005
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • diagnosis of chronic periodontitis
  • presence of at least one pair of interproximal infrabony defects (2-3 walls) adjacent to vital anterior or premolar teeth
  • absence of 2 and 3 mobility degrees
  • probing pocket depth (PPD)≥ 5mm
  • full-mouth plaque score ≤ 20%
  • keratinized tissue width of at least 2mm

Who cannot join

  • presence of any systemic disease that could interfere with periodontal treatment
  • infrabony defects with trans-surgical depth ≤4mm
  • antibiotic treatment administered during the last 6 months -

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Faculdade de Odontologia da Universidade de São Paulo (FOUSP)

    São Paulo, São Paulo

Other trials in Brazil

About this study

Official title: Two-year Randomized Clinical Trial of Enamel Matrix Derivative Treated Infrabony Defects: Radiographic Analysis

This is a split-mouth, double-blind randomized controlled trial. Computerized linear radiographic measurements were used to detect infrabony defects treated with open flap debridement (OFD) or OFD associated with enamel matrix derivative (EMD), after 24 months. Ten patients presenting 2 or more defects were selected (43 defects). An individualized film holder was used to take standardized radiographs at baseline and after 24 months. Images were digitized and used to measure the distances from the cemento-enamel junction (CEJ) to the alveolar crest (AC), CEJ to the bottom of the defect (BD) and infrabony defect angle.

Read the detailed description

This was a split-mouth randomized controlled trial. Patients were recruited among the ones seeking for periodontal treatment at the Post-graduate Clinic of Periodontics using the following inclusion criteria: (1) diagnosis of chronic periodontitis15; (2) presence of at least one pair of interproximal infrabony defects (2-3 walls) adjacent to vital anterior or premolar teeth; (3) absence of 2 and 3 mobility degrees16; (4) probing pocket depth (PPD)≥ 5mm; (5) full-mouth plaque score ≤ 20%17; and (6) keratinized tissue width of at least 2mm. The exclusion criteria were: (1) presence of any systemic disease that could interfere with periodontal treatment; (2) infrabony defects with trans-surgical depth ≤4mm; (3) antibiotic treatment administered during the last 6 months.

The patients participating in the study were volunteers who received and gave informed consent and were included in the study from June to October 2002.

Following initial examination, all patients underwent oral hygiene instruction and full-mouth supra- and sub-gingival scaling and root planning under local anesthesia. Patients were re-evaluated after completion of the initial therapy to determine their response to therapy and to confirm the need for periodontal surgery. Before surgery, for each pair of defects, one defect was randomly assigned to test (EMD) and one to control (OFD) treatment by toss of a coin. Both defects were treated at the same surgical time. When a patient presented with more than one pair of defects, only one pair was treated per day. Following local anesthesia, all sites were treated with reflection of a full thickness mucoperiosteal flap after intra-sulcular incisions. The exposed roots and osseous defects were debrided with hand instruments, and the surgical wound was rinsed with saline.

After that, the flaps of the OFD sites were repositioned and sutured using 5-0 nylon sutures. The EMD sites were dried with non-woven gauze, roots were conditioned with 24% ethylenediaminotetracetic acid (EDTA) gel (pH 6.7) for 2 minutes. The defect was thoroughly rinsed with saline, and EMD gel was applied to the root surfaces according to the manufacturer's instructions. The flaps were then replaced for primary closure and sutured with 5-0 nylon sutures. The sutures were removed after 7 days. All surgeries were performed by the same investigator. All patients were prescribed 0.12% chlorhexidine digluconate and instructed to rinse gently twice a day for 4 weeks. Analgesics were prescribed to be taken as needed, and all patients were seen once a week, for 8 weeks, for professional tooth cleaning. Subsequently, the patients were maintained in a supportive periodontal program (ie, professional tooth cleaning and reinforcement of self-administered oral hygiene measures) at 2-month intervals up to 6-month time and then every 3 months until final examination at 24 months.

Standardized periapical radiographs were taken at baseline evaluation, immediately before surgery and at 24 months follow-up. Individually customized bite blocks employing a reference occlusal stent and film holders were used to obtain reproducible exposed films at each radiographic control. All radiographs were evaluated by a single calibrated examiner, blind to time and treatment.

Analyses of the radiographic outcomes were performed using computerized linear measurements with image analysis software. The radiographs were previously scanned in digital format by a scanner at a resolution of 500dpi/8bits.

The radiographic analysis was based in anatomical landmarks (CEJ, BD and AC) that were identified on the scanned radiographs. All linear measurements were recorded by a blinded, calibrated examiner. The following outcomes were measured at radiographs taken at baseline and after 24 months:

  1. Distance from the CEJ to the bottom of the defect (BD). The most coronal area where the periodontal ligament maintained an even width was identified to measure the most apical extension of the infrabony defect;
  2. Distance from the CEJ to the bone crest (BC);
  3. Infrabony defect angle was defined by two lines that represented the root surface of the involved tooth (CEJ-BD) and the bone defect surface (BD-BC).

The distance from the CEJ to the bottom of the defect (BD) was considered the primary outcome. CEJ-BC and defect angle were secondary outcomes

Being tested
enamel matrix derivative, Open flap debridement
Keywords
Chronic Periodontitis, Periodontal disease
Medical subject headings
Chronic Periodontitis, Periodontal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • enamel matrix derivativeDrug

    Also called Emdogain, Straumann

    Open flap debridement associated with enamel matrix derivative

  • Open flap debridementProcedure or surgery

    Open flap debridement

Study groups in NCT02195765
Study groupRoleWhat they receive
enamel matrix derivativeExperimentalOpen flap debridement associated with Enamel matrix derivative gel (Emdogain, Straumann)
Receives: Drug: enamel matrix derivative; Procedure: Open flap debridement
Open flap debridmentActive comparatorOpen flap debridement
Receives: Procedure: Open flap debridement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Distance from the cemento-enamel junction (CEJ) to the bottom of the defect (BD)

    The most coronal area where the periodontal ligament maintained an even width was identified to measure the most apical extension of the infrabony defect

    Measured: 24 months

Secondary outcomes (2)
  1. Distance from the CEJ to the bone crest

    Measured: 24 months

  2. Infrabony defect angle

    Infrabony defect angle was defined by two lines that represented the root surface of the involved tooth (CEJ-BD) and the bone defect surface (BD-BC)

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jul 2014 (estimated)
  2. Study startJun 2002
  3. Primary completionOct 2004
  4. Study completionOct 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
48 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02195765
Sponsor's protocol ID
EMD24
Status last verified
Jul 2014
First submitted
16 Jul 2014
Last updated
21 Jul 2014
Results posted
No
Data monitoring committee
No

Publications

  • Chambrone D, Pasin IM, Chambrone L, Pannuti CM, Conde MC, Lima LA. Treatment of infrabony defects with or without enamel matrix proteins: a 24-month follow-up randomized pilot study. Quintessence Int. 2010 Feb;41(2):125-34.

    PubMed 20165744
  • Chambrone D, Pasin IM, Conde MC, Panutti C, Carneiro S, Lima LA. Effect of enamel matrix proteins on the treatment of intrabony defects: a split-mouth randomized controlled trial study. Braz Oral Res. 2007 Jul-Sep;21(3):241-6. doi: 10.1590/s1806-83242007000300009.

    PubMed 17710290
  • Ragghianti Zangrando MS, Chambrone D, Pasin IM, Conde MC, Pannuti CM, de Lima LA. Two-year randomized clinical trial of enamel matrix derivative treated infrabony defects: radiographic analysis. BMC Oral Health. 2014 Dec 4;14:149. doi: 10.1186/1472-6831-14-149.

    PubMed 25475143

Questions about this trial

What is this clinical trial studying?

A study testing enamel matrix derivative and Open flap debridement in people with Chronic Periodontitis, run by University of Sao Paulo at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Distance from the cemento-enamel junction (CEJ) to the bottom of the defect (BD) (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02195765, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in